The Drug Monitoring and Abuse Testing
- Drugs of abuse testing sales will reach $1.6 billion in 2007, rising at an AAGR (average annual growth rate) of 4.7%.
- Sales in the U.S. are expected to reach $996 million in 2002 and forecasted to grow to $1.3 billion in 2007 at an AAGR of 5.4%.
- Sales in Europe expected to be $291 million in 2002 and forecasted to grow at an AAGR of 1.8% to approximately $318 million in 2007.
- The number of different places and applications, such as a workplace, drug court, hospital, and school, for drug testing, with blood, hair, oral fluid, sweat or urine samples, reflects the need for a variety of drug testing services and the versatility of drug testing technology.
STUDY GOAL AND OBJECTIVES
This study provides a comprehensive analysis of available and emerging diagnostics for the drugs of abuse testing market. Its aim is to provide a range of information¾from detailed product analyses through industry trends¾to quantify and qualify the market for drugs of abuse testing products. Forecasts of product categories and industry trends are provided for the U.S. market and, when available, for international markets. Forecasts and trends are gleaned from interviews with industry sources as well as from considered assessment of available and emerging technologies.
REASONS FOR DOING THE STUDY
Testing for drug use and abuse has evolved at a dramatic rate from a small minority of companies testing employees for substance abuse in the mid-1980s to the practice becoming standard in almost all government agencies and large corporate firms in the 1990s. Legislation requiring the testing of all transportation industry workers, as well as court decisions upholding the legality of testing high school students, is making drug testing commonplace in all segments of society. Overall, the drugs of abuse market is projected to witness average annual growth of about 4.7% from 2002 to 2007.
Along with the dramatic expansion in scope, the methods of testing for drug use and abuse are undergoing change. The standard urine test, which is still the most widely utilized, is being challenged by new, more sensitive, and technologically sophisticated techniques, such as meconium, oral fluid, and hair analysis. Less invasive, more sensitive technologies that are capable of detecting as many as 40 compounds in one analysis are moving this market into a higher degree of sophistication to meet increasing demand. Markets that have been small or non-existent, such as home drug testing, roadside drug testing, and school drug testing, are developing due to technology and policy developments.
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
This report provides a thorough background of the drugs of abuse testing market; it offers information needed to understand the current market and to approach the emerging one. It is an invaluable tool for planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investor consultants, and anyone interested in the drugs of abuse testing market, its products, its industry participants, and its future.
SCOPE AND FORMAT
This report offers forecasts by product segment from 2002 through 2007, including supporting analyses for all projections. Product segments include drug testing devices by sample specimen, which includes blood, hair, oral fluid, sweat, and urine.
Diagnostic technologies discussed include enzyme immunoassays, enzyme multiplied immunoassay techniques, fluorescence polarization immunoassays, radioimmuno-assays, and various chromatography techniques.
The study is arranged to offer an overview of the drugs of abuse testing market accompanied by analyses and forecasts by product type and application. International markets are discussed, as well as information on industry structure and the regulatory environment. Profiles of leading manufacturers of drugs of abuse diagnostics provide information on placement within the market and strategic analyses of each company's available and emerging products.
Information to prepare this study was derived from interviews with product managers, marketing strategists, research executives, and others at leading companies in the drugs of abuse testing industry. Interviews also were conducted with researchers and product planners at companies that do not participate yet in this market but which are developing products to be introduced during the forecast period. Discussions were held also with government agencies and regulatory bodies that monitor, regulate, or monitor and regulate drug testing in the workplace. Searches of secondary material such as company annual reports and 10Ks, journal articles, prospectus assessments, government resources, and health care institutions' data were conducted also.
Information to prepare this report was obtained from primary interviews with companies, industry analysts, health care personnel, the National Institute on Drug Abuse and other government agencies, literature searches, annual reports, 10Ks, and product literature.